Septerna, Inc. (SEPN) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
9.80
↓-13% vs avg
5yr avg: 11.25
30Y Low11.3·High11.3
P/B Ratio
↑
2.78
↑+47% vs avg
5yr avg: 1.89
30Y Low0.5·High3.2
ROE
↑
-12.2%
↓+51% vs avg
5yr avg: -24.9%
30Y Low-38%·High-12%
Debt/EBITDA
N/A
—
5yr avg: 4.30
30Y Low4.3·High4.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SEPN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Septerna, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 9.8x P/FCF, 13% below the 5-year average of 11.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.2B | $227M | — | — |
| Enterprise Value | $977M | $1.1B | $14M | — | — |
| P/E Ratio → | -21.80 | — | — | — | — |
| P/S Ratio | 23.38 | 26.85 | 210.70 | — | — |
| P/B Ratio | 2.78 | 3.23 | 0.54 | — | — |
| P/FCF | 9.80 | 11.25 | — | — | — |
| P/OCF | 9.75 | 11.20 | — | — | — |
P/E links to full P/E history page with 30-year chart
SEPN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | 24.74 | 12.82 | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | 10.37 | — | — | — |
SEPN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Septerna, Inc. earns an operating margin of -148.6%. Operating margins have compressed from 1374.2% to -148.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -12.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Operating Margin | -148.6% | -148.6% | -7518.4% | 1374.2% | — |
| Net Profit Margin | -106.4% | -106.4% | -6678.9% | 2768.2% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -12.2% | -12.2% | -37.6% | — | — |
| ROA | -9.3% | -9.3% | -24.4% | 5.0% | -76.6% |
| ROIC | -20.8% | -20.8% | -130.3% | — | — |
| ROCE | -14.3% | -14.3% | -28.5% | 2.7% | -91.5% |
SEPN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $121M exceeds total debt of $24M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | 4.30 | — |
| Net Debt / Equity | — | -0.25 | -0.51 | — | — |
| Net Debt / EBITDA | — | — | — | -25.97 | — |
| Debt / FCF | — | -0.89 | — | — | — |
| Interest Coverage | — | — | — | — | — |
Net cash position: cash ($121M) exceeds total debt ($24M)
SEPN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Septerna, Inc.'s current ratio of 4.73x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 16.30x to 4.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 4.73 | 4.73 | 27.77 | 16.30 | 5.75 |
| Quick Ratio | 4.73 | 4.73 | 27.77 | 16.30 | 5.75 |
| Cash Ratio | 4.50 | 4.50 | 27.31 | 12.80 | 5.52 |
| Asset Turnover | — | 0.08 | 0.00 | 0.00 | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | 82.26 | 381.64 | 55054.57 | — |
SEPN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Septerna, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | 10.2% | 8.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $44M | $10M | $19M | $19M |
Peer Comparison
Compare SEPN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SEPNYou | $1B | -21.8 | — | 9.8 | — | -148.6% | -12.2% | -20.8% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RXRX | $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 VKTX | $4B | -9.9 | — | — | — | — | -47.3% | -44.4% | — |
 GPCR | $2B | -16.3 | — | — | — | — | -11.9% | -30.3% | — |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 CGEM | $905M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See SEPN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SEPN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SEPN vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonSEPN — Frequently Asked Questions
Quick answers to the most common questions about buying SEPN stock.
What is Septerna, Inc.'s P/E ratio?
Septerna, Inc.'s current P/E ratio is -21.8x. This places it at the 50th percentile of its historical range.
What is Septerna, Inc.'s ROE?
Septerna, Inc.'s return on equity (ROE) is -12.2%. The historical average is -24.9%.
Is SEPN stock overvalued?
Based on historical data, Septerna, Inc. is trading at a P/E of -21.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Septerna, Inc.'s profit margins?
Septerna, Inc. has -148.6% operating margin.